Imugene Limited (AU:IMU) has released an update.
Imugene Limited, a clinical-stage immuno-oncology company, has announced the release of 31,496,415 fully paid ordinary shares from voluntary escrow on August 7, 2024. These shares were originally issued to vendors of Vaxinia Pty Ltd following shareholder approval in 2019. Imugene focuses on developing immunotherapies to activate cancer patients’ immune systems and eradicate tumors, with a product pipeline that includes CAR T therapies and oncolytic virotherapy.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
